Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Velcade with R-CHOP in Mediastinal Large B-cell Lymphoma
NCT00361621Phase 2Terminated
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Jul 2006
- Primary completion
- Nov 2007
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in primary mediastinal large B-cell lymphoma (PMBCL), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Rate of Complete Response at 1 year. Started Jul 2006; status: terminated.
02
Drugs
bortezomib
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)
Beyond the preview
Go deeper on NCT00361621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00361621.